Method for enhancing the DNA repair process, treating disorders associated with the DNA repair process, enhancing antitumor response and treating disorders associated with anti-tumor response in mammals by administering purified quinic acid and/or carboxy alkyl ester
DC
First Claim
Patent Images
1. A method for enhancing the DNA repair process of a mammal in need thereof by inhibiting TNF-α
- production or inducing apoptosis of white blood cells, comprising administering to said mammal a pharmaceutical composition comprising a pharmaceutically effective amount of a purified, isolated quinic acid alkyl ester having a UV absorption maximum at approximately 200 nm and a bioassay efficacy using IC50 in HL-60 cells of less than 100 μ
g/ml, where said amount is effective to inhibit TNF-α
production or to induce apoptosis of white blood cells, and where said administration is other than topical.
1 Assignment
Litigations
0 Petitions
Accused Products
Abstract
For use in mammals, methods for enhancing the DNA repair process, treating disorders associated with the DNA repair process, enhancing anti-tumor response and treating disorders associated with anti-tumor response. The methods generally comprise non-topical administration of purified, isolated quinic acid alkyl acid or a carboxy alkyl ester with a non-toxic carrier or diluent.
15 Citations
20 Claims
-
1. A method for enhancing the DNA repair process of a mammal in need thereof by inhibiting TNF-α
- production or inducing apoptosis of white blood cells, comprising administering to said mammal a pharmaceutical composition comprising a pharmaceutically effective amount of a purified, isolated quinic acid alkyl ester having a UV absorption maximum at approximately 200 nm and a bioassay efficacy using IC50 in HL-60 cells of less than 100 μ
g/ml, where said amount is effective to inhibit TNF-α
production or to induce apoptosis of white blood cells, and where said administration is other than topical. - View Dependent Claims (2, 3, 4, 5)
- production or inducing apoptosis of white blood cells, comprising administering to said mammal a pharmaceutical composition comprising a pharmaceutically effective amount of a purified, isolated quinic acid alkyl ester having a UV absorption maximum at approximately 200 nm and a bioassay efficacy using IC50 in HL-60 cells of less than 100 μ
-
6. A method for treating disorders associated with the DNA repair process of a mammal in need thereof by inhibiting TNF-α
- production or inducing apoptosis of white blood cells, comprising administering to said mammal a pharmaceutical composition comprising a pharmaceutically effective amount of a purified, isolated quinic acid alkyl ester having a UV absorption maximum at approximately 200 nm and a bioassay efficacy using IC50 in HL-60 cells of less than 100 μ
g/ml, where said amount is effective to inhibit TNF-α
production or to induce apoptosis of white blood cells, and where said administration is other than topical. - View Dependent Claims (7, 8, 9, 10)
- production or inducing apoptosis of white blood cells, comprising administering to said mammal a pharmaceutical composition comprising a pharmaceutically effective amount of a purified, isolated quinic acid alkyl ester having a UV absorption maximum at approximately 200 nm and a bioassay efficacy using IC50 in HL-60 cells of less than 100 μ
-
11. A method for enhancing the DNA repair process of a mammal in need thereof by inhibiting TNF-α
- production or inducing apoptosis of white blood cells, comprising administering to said mammal a pharmaceutical composition comprising a pharmaceutically effective amount of a purified, isolated carboxy alkyl ester where said amount is effective to inhibit TNF-α
production or to induce apoptosis of white blood cells, where said carboxy alkyl ester is characterized by having a UV absorption maximum at approximately 200 nm, absorbs onto charcoal, and reacts with hydroxylamine and ferric chloride, and where said administration is other than topical. - View Dependent Claims (12, 13, 14, 15)
- production or inducing apoptosis of white blood cells, comprising administering to said mammal a pharmaceutical composition comprising a pharmaceutically effective amount of a purified, isolated carboxy alkyl ester where said amount is effective to inhibit TNF-α
-
16. A method for treating disorders associated with the DNA repair process of a mammal in need thereof by inhibiting TNF-α
- production or inducing apoptosis of white blood cells, comprising administering to said mammal a pharmaceutical composition comprising a pharmaceutically effective amount of a purified, isolated carboxy alkyl ester where said amount is effective to inhibit TNF-α
production or to induce apoptosis of white blood cells, where said carboxy alkyl ester is characterized by having a UV absorption maximum at approximately 200 nm, absorbs onto charcoal, and reacts with hydroxylamine and ferric chloride, and where said administration is other than topical. - View Dependent Claims (17, 18, 19, 20)
- production or inducing apoptosis of white blood cells, comprising administering to said mammal a pharmaceutical composition comprising a pharmaceutically effective amount of a purified, isolated carboxy alkyl ester where said amount is effective to inhibit TNF-α
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
Litigation Data
-
Current AssigneeOptigenex Incorporated
-
Original AssigneeOptigenex Incorporated
-
InventorsPero, Ronald W.
-
Primary Examiner(s)TATE, CHRISTOPHER ROBIN
-
Application NumberUS12/504,845Publication NumberTime in Patent Office690 DaysField of SearchNoneUS Class Current424/725CPC Class CodesA61K 36/74 Rubiaceae (Madder family)A61P 29/00 Non-central analgesic, anti...A61P 35/00 Antineoplastic agentsA61P 37/02 ImmunomodulatorsA61P 37/04 ImmunostimulantsA61P 37/06 Immunosuppressants, e.g. dr...A61P 43/00 Drugs for specific purposes...
